Novartis
Novartis’ new drug muscles in on Pfizer’s territory
October 10, 2016Sales and Marketing Eli Lilly, Novartis, Pfizer, ibrance, ribociclib
A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …
Novartis reveals impressive four year data upon Cosentyx
October 3, 2016Sales and Marketing Cosentyx, Novartis, psoriasis
Novartis announced on October 1 that Cosentyx (secukinumab) had delivered a high percentage and long-lasting skin clearance in patients with …
Novartis’ Zykadia smashes Phase III target for lung cancer
September 23, 2016Medical Communications, Research and Development Novartis, lung cancer, zykadia
Novartis has announced that its cancer drug Zykadia (ceritinib) has achieved positive results in its Phase III clinical trial investigating …
Novartis joins $17m funding of chronic inflammatory disease startup
September 14, 2016Research and Development Fountain Healthcare, Novartis, start up financing
Novartis was one of the co-leaders in the $17million series A financing of Irish startup in the development of chronic …
Top ten stories in the pharmaceutical industry this week
September 9, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis
It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …
Up to 120 jobs set to go as Novartis closes down Cell and Gene Therapies unit
September 1, 2016Manufacturing and Production, Research and Development CAR-T, Novartis, cart, cell and gene therapies
News has emerged that Novartis plans to close down its Cell and Gene Therapies unit, with up to 120 workers …
FDA approves Novartis Enbrel biosimilar
August 31, 2016Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar, erzeli
Novartis, through its Sandoz division, has announced that the FDA has approved Erelzi (etanercept-szzs), a biosimilar of Amgen’s blockbuster drug …
Positive Phase III results for Novartis MS drug
August 25, 2016Research and Development Novartis, multiple sclerosis, phase III
Novartis has announced positive Phase III results for its EXPAND study, an evaluation of the efficacy and safety of orally-administered, …
NICE says Afinitor and Imbruvica “may be removed” from Cancer Drugs Fund
August 18, 2016Research and Development, Sales and Marketing Afinitor, Cancer Drugs Fund, Janssen, NICE, Novartis, imbruvica
NICE has published draft guidance advising the removal of Novartis’s Afinitor (everolimus) and Janssen’s Imbruvica (ibrutinib) from the Cancer Drugs …
Novartis invests €100 million to expand French manufacturing plant
August 15, 2016Manufacturing and Production, Sales and Marketing Novartis, manufacturing
Novartis has sealed the deal with construction firm Jacobs Engineering group to expand production operations at its France Center of …
Novartis admits employees gave kickbacks to doctors in South Korea
August 12, 2016Medical Communications, Research and Development Novartis, kickbacks, south korea
Novartis has confirmed that six employees in South Korea gave kickbacks to doctors, as the current and former employees face …
Apellis Pharmaceuticals appoints Dr Robert Kim as CMO
August 8, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Apellis, CMO, GSK, Novartis, appointment
Clinical stage complement immunotherapy company Apellis Pharmaceuticals has named its new chief medical officer as Dr Robert Kim. Kim’s primary …
‘Game changer’ asthma pill sees significant reduction in severe symptoms
August 8, 2016Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, university of Leicester
A study at the University of Leicester has found that Fevipiprant (QAW039), the first new asthma pill for nearly 20 …
Top ten stories in the pharmaceutical industry this week
August 5, 2016Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten
It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …
NICE recommends Cosentyx in ankylosing spondylitis
August 4, 2016Research and Development, Sales and Marketing Cosentyx, NICE, Novartis, ankylosing spondylitis
Novartis has announced that the National Institute for Health and Care Excellence (NICE) has recommended Cosentyx (secukinumab) to treat adults …
Latest content
FibroFind appoints Lee Borthwick as CEO
